Evidence map›Paper›PMID 35158767›Full record

ArticleCancers2022

Sphingosine Kinase-1 Is Overexpressed and Correlates with Hypoxia in Osteosarcoma: Relationship with Clinicopathological Parameters.

Anne Gomez-Brouchet, Claire Illac, Adeline Ledoux, Pierre-Yves Fortin, Sandra de Barros, Clémentine Vabre, Fabien Despas, Sophie Peries, Christelle Casaroli, Corinne Bouvier and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 2 countries.

Anne Gomez-BrouchetCNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.
Claire IllacCNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.
Adeline LedouxCNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.
Pierre-Yves FortinCNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.
Sandra de BarrosService de Pharmacologie Clinique, Hôpitaux de Toulouse, 31300 Toulouse, France.
Clémentine VabreService de Pharmacologie Clinique, Hôpitaux de Toulouse, 31300 Toulouse, France.
Fabien DespasService de Pharmacologie Clinique, Hôpitaux de Toulouse, 31300 Toulouse, France.
Sophie PeriesService de Pharmacologie Clinique, Hôpitaux de Toulouse, 31300 Toulouse, France.
Christelle CasaroliCancer Biobank, Institut Universitaire du Cancer de Toulouse-Oncopôle (IUCT-O), 31059 Toulouse, France.
Corinne BouvierDepartment of Pathology, CHU la Timone, 13005 Marseille, France.
Sébastien AubertDepartment of Pathology, CHRU de Lille, 50037 Lille, France.
Gonzague de PinieuxDepartment of Pathology, CHU de Tours, 37044 Tours, France.
Frédérique LarousserieDepartment of Pathology, AP-HP, Hôpital Cochin, Universiteé Paris Descartes, 75014 Paris, France.
Louise GalmicheCentre Hospitalier Universitaire de Nantes Hôtel Dieu, 44000 Nantes, France.
Franck TalmontCNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.ORCID 0000-0003-4933-5816
Stuart PitsonCentre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA 5000, Australia.ORCID 0000-0002-9527-2740
Marie-Lise MaddeleinCNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.
Olivier CuvillierCNRS, Institut de Pharmacologie et de Biologie Structurale, 31077 Toulouse, France.ORCID 0000-0003-3346-375X
Centre National de la Recherche Scientifique · FRCentre Hospitalier Universitaire de Lille · FRCentre Hospitalier Universitaire de Nantes · FRCentre Hospitalier Universitaire de Tours · FRHôpital de la Timone · FRInstitut universitaire du cancer de Toulouse Oncopole · FRSouth Australia Pathology · AUUniversité Paris Cité · FR

Funding

Ligue Nationale contre le Cancer NA
6 · The paper itself

Abstract

The Sphingosine kinase-1/Sphingosine 1-Phosphate (SphK1/S1P) signaling pathway is overexpressed in various cancers, and is instrumental for the adaptation to hypoxia in a number of solid tumor models, but no data are available in osteosarcoma. Here we report that SphK1 and the S1P

Indexed as

fingolimodFTY720GLUT-1HIFosteosarcomaS1P1sphingosine kinase

Identifiers

PMID35158767
PMCPMC8833796
OpenAlexW3191765468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.